FIRST CLASS MAIL CERTIFICATE

3652

ktoreby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner of Patents and Trademarks, United States Patent and Trademark Office, Washington, D.C. 20231.

Mulae, fallalino Linda O. Palladino

September 10, 2001

SEP 17 200°.

O 3600 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of

Xia, et al.

RECEIVED

USSN

09/773,877

SEP 2 5 2001 TECH CENTER 1600/2900

Filed

January 31, 2001

1

For

METHODS OF TREATING

INFLAMMATORY DISEASES

Examiner

Not Yet Known

Group

Not Yet Known

September 10, 2001

Commissioner for Patents U.S. Patent and Trademark Office Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.§1.97(c) AND 1.98

SIR:

Submitted herewith is PTO Form 1449 to make of record those references of which Applicants are aware which may be pertinent to an examination of the captioned patent application on the merits. Copies of the listed references are enclosed.

Att. Dkt. No. REG 710B USSN: 09/773,877 Transmittal of IDS Page 2

No fee is deemed necessary in connection with filing this Information Disclosure Statement. However, if any additional fee is necessary, authorization is hereby given to charge the amount of any such additional fee to Deposit Account No. 18-0650.

Respectfully submitted,

Gail M. Kempler Reg. No. 32,143

Joseph M. Sorrentino

Reg. No. 32,598

Attorneys for Applicants

Linda O. Palladino

Reg. No. 45,636

Patent Agent for Applicants Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400